PMID- 27625357
OWN - NLM
STAT- MEDLINE
DCOM- 20170925
LR  - 20210202
IS  - 1528-0020 (Electronic)
IS  - 0006-4971 (Print)
IS  - 0006-4971 (Linking)
VI  - 128
IP  - 19
DP  - 2016 Nov 10
TI  - Late acute graft-versus-host disease: a prospective analysis of clinical outcomes 
      and circulating angiogenic factors.
PG  - 2350-2358
LID - 10.1182/blood-2015-09-669846 [doi]
AB  - Late acute (LA) graft-versus-host disease (GVHD) is persistent, recurrent, or 
      new-onset acute GVHD symptoms occurring >100 days after allogeneic hematopoietic 
      cell transplantation (HCT). The aim of this analysis is to describe the onset, 
      course, morbidity, and mortality of and examine angiogenic factors associated 
      with LA GVHD. A prospective cohort of patients (n = 909) was enrolled as part of 
      an observational study within the Chronic GVHD Consortium. Eighty-three patients 
      (11%) developed LA GVHD at a median of 160 (interquartile range, 128-204) days 
      after HCT. Although 51 out of 83 (61%) achieved complete or partial response to 
      initial therapy by 28 days, median failure-free survival was only 7.1 months (95% 
      confidence interval, 3.4-19.1 months), and estimated overall survival (OS) at 2 
      years was 56%. Given recently described alterations of circulating angiogenic 
      factors in classic acute GVHD, we examined whether alterations in such factors 
      could be identified in LA GVHD. We first tested cases (n = 55) and controls (n = 
      50) from the Chronic GVHD Consortium and then validated the findings in 37 cases 
      from Mount Sinai Acute GVHD International Consortium. Plasma amphiregulin (AREG; 
      an epidermal growth factor [EGF] receptor ligand) was elevated, and an AREG/EGF 
      ratio at or above the median was associated with inferior OS and increased 
      nonrelapse mortality in both cohorts. Elevation of AREG was detected in classic 
      acute GVHD, but not chronic GVHD. These prospective data characterize the 
      clinical course of LA GVHD and demonstrate alterations in angiogenic factors that 
      make LA GVHD biologically distinct from chronic GVHD.
CI  - (c) 2016 by The American Society of Hematology.
FAU - Holtan, Shernan G
AU  - Holtan SG
AD  - Hematology, Oncology and Transplant, University of Minnesota, Minneapolis, MN.
FAU - Khera, Nandita
AU  - Khera N
AD  - Mayo Clinic, Phoenix, AZ.
FAU - Levine, John E
AU  - Levine JE
AD  - Blood and Marrow Transplantation Program, The Icahn School of Medicine at Mount 
      Sinai, New York, NY.
FAU - Chai, Xiaoyu
AU  - Chai X
AD  - Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
FAU - Storer, Barry
AU  - Storer B
AD  - Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
FAU - Liu, Hien D
AU  - Liu HD
AD  - Blood and Marrow Transplant Program, Cleveland Clinic, Cleveland, OH.
FAU - Inamoto, Yoshihiro
AU  - Inamoto Y
AD  - Stem Cell Transplantation Division, National Cancer Center Hospital, Tokyo, 
      Japan.
FAU - Chen, George L
AU  - Chen GL
AD  - Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY.
FAU - Mayer, Sebastian
AU  - Mayer S
AD  - Department of Medicine, Weill Cornell Medical Center, New York, NY.
FAU - Arora, Mukta
AU  - Arora M
AD  - Hematology, Oncology and Transplant, University of Minnesota, Minneapolis, MN.
FAU - Palmer, Jeanne
AU  - Palmer J
AD  - Mayo Clinic, Phoenix, AZ.
FAU - Flowers, Mary E D
AU  - Flowers MED
AD  - Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
FAU - Cutler, Corey S
AU  - Cutler CS
AD  - Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, 
      Boston, MA.
FAU - Lukez, Alexander
AU  - Lukez A
AD  - Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, 
      Boston, MA.
FAU - Arai, Sally
AU  - Arai S
AD  - Division of Blood and Marrow Transplantation, Stanford University Medical Center, 
      Stanford, CA.
FAU - Lazaryan, Aleksandr
AU  - Lazaryan A
AD  - Hematology, Oncology and Transplant, University of Minnesota, Minneapolis, MN.
FAU - Newell, Laura F
AU  - Newell LF
AD  - Center for Hematologic Malignancies, Oregon Health and Science University, 
      Portland, OR.
FAU - Krupski, Christa
AU  - Krupski C
AD  - Division of Hematology/Oncology, Stem Cell Transplantation, Department of 
      Medicine, Vanderbilt University Medical Center, Nashville, TN.
FAU - Jagasia, Madan H
AU  - Jagasia MH
AD  - Division of Hematology/Oncology, Stem Cell Transplantation, Department of 
      Medicine, Vanderbilt University Medical Center, Nashville, TN.
FAU - Pusic, Iskra
AU  - Pusic I
AD  - Medical Oncology, Washington University Medical Center, St. Louis, MO.
FAU - Wood, William
AU  - Wood W
AD  - Hematology/Oncology, University of North Carolina Healthcare, Chapel Hill, NC.
FAU - Renteria, Anne S
AU  - Renteria AS
AD  - Blood and Marrow Transplantation Program, The Icahn School of Medicine at Mount 
      Sinai, New York, NY.
FAU - Yanik, Gregory
AU  - Yanik G
AD  - Blood and Marrow Transplantation Program, University of Michigan, Ann Arbor, MI.
FAU - Hogan, William J
AU  - Hogan WJ
AD  - Blood and Marrow Transplantation Program, Mayo Clinic, Rochester, MN.
FAU - Hexner, Elizabeth
AU  - Hexner E
AD  - Abramson Cancer Center, University of Pennsylvania, Philadelphia PA.
FAU - Ayuk, Francis
AU  - Ayuk F
AD  - Department of Stem Cell Transplantation, University Medical Center, 
      Hamburg-Eppendorf, Germany.
FAU - Holler, Ernst
AU  - Holler E
AD  - Blood and Marrow Transplantation Program, University of Regensburg, Regensburg, 
      Germany.
FAU - Watanaboonyongcharoen, Phandee
AU  - Watanaboonyongcharoen P
AD  - Blood and Marrow Transplantation Program, Chulalongkorn University, Bangkok, 
      Thailand.
FAU - Efebera, Yvonne A
AU  - Efebera YA
AD  - Blood and Marrow Transplantation Program, Ohio State University, Columbus, OH; 
      and.
FAU - Ferrara, James L M
AU  - Ferrara JLM
AD  - Blood and Marrow Transplantation Program, The Icahn School of Medicine at Mount 
      Sinai, New York, NY.
FAU - Panoskaltsis-Mortari, Angela
AU  - Panoskaltsis-Mortari A
AD  - Hematology, Oncology and Transplant, University of Minnesota, Minneapolis, MN.
FAU - Weisdorf, Daniel
AU  - Weisdorf D
AD  - Hematology, Oncology and Transplant, University of Minnesota, Minneapolis, MN.
FAU - Lee, Stephanie J
AU  - Lee SJ
AD  - Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
FAU - Pidala, Joseph
AU  - Pidala J
AD  - Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research 
      Institute, Tampa, FL.
LA  - eng
GR  - UG1 HL069249/HL/NHLBI NIH HHS/United States
GR  - U54 CA163438/CA/NCI NIH HHS/United States
GR  - R01 CA118953/CA/NCI NIH HHS/United States
GR  - P01 CA039542/CA/NCI NIH HHS/United States
GR  - U01 CA118953/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20160913
PL  - United States
TA  - Blood
JT  - Blood
JID - 7603509
RN  - 0 (Angiogenesis Inducing Agents)
SB  - IM
CIN - Blood. 2016 Nov 10;128(19):2282-2283. PMID: 28829752
MH  - Acute Disease
MH  - Adult
MH  - Aged
MH  - Angiogenesis Inducing Agents/*blood
MH  - Case-Control Studies
MH  - Chronic Disease
MH  - Female
MH  - Graft vs Host Disease/*blood/diagnosis/*therapy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Morbidity
MH  - Prospective Studies
MH  - Treatment Outcome
MH  - Young Adult
PMC - PMC5106113
EDAT- 2016/09/15 06:00
MHDA- 2017/09/26 06:00
PMCR- 2017/11/10
CRDT- 2016/09/15 06:00
PHST- 2015/09/11 00:00 [received]
PHST- 2016/08/17 00:00 [accepted]
PHST- 2016/09/15 06:00 [pubmed]
PHST- 2017/09/26 06:00 [medline]
PHST- 2016/09/15 06:00 [entrez]
PHST- 2017/11/10 00:00 [pmc-release]
AID - S0006-4971(20)33996-3 [pii]
AID - 2015/669846 [pii]
AID - 10.1182/blood-2015-09-669846 [doi]
PST - ppublish
SO  - Blood. 2016 Nov 10;128(19):2350-2358. doi: 10.1182/blood-2015-09-669846. Epub 
      2016 Sep 13.